Loading
Beijing Xunsheng Biomedical Research grows a patient's own tumour-fighting immune cells, taken from the tumour itself, and gives them back in large numbers. Its first cell therapy, ReT01, is aimed at cervical cancer and is in an early trial in advanced solid tumours; it is also developing DNA vaccines against HPV.
Beijing Xunsheng Biomedical Research Co., Ltd. (Aeonvital), headquartered at the Zhongguancun (Daxing) cell and gene therapy park in Daxing, Beijing, was founded in March 2021, according to the company. It develops tumour-infiltrating lymphocyte (TIL) therapies using its TILAmp expansion platform and LentiVae lentiviral gene-modification platform, and nucleic-acid (DNA and mRNA) therapeutic vaccines using an engineered bacterial vector platform. The company describes ReT01 as China's first natural TIL product for cervical cancer, given without lymphodepletion and without IL-2 injection, and reports implied clinical trial approval from the National Medical Products Administration; a phase 1 study of ReT01 ACT in advanced solid tumours is registered (NCT06257680). AVL-101 is a DNA-based therapeutic HPV vaccine that started a phase 1 study in 2026, according to company news. Founded in 2021, according to the company. Its first registered cancer trial, NCT06257680, was posted on ClinicalTrials.gov in February 2024.
Shares TIL therapy, Cervical cancer.
Shares TIL therapy, Cervical cancer.
Shares TIL therapy, Cervical cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/